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http://www.microbialcellfactories.com/content/12/1/124RESEARCH Open AccessAn improved Bacillus subtilis cell factory for
producing scyllo-inositol, a promising therapeutic
agent for Alzheimer’s disease
Kosei Tanaka1, Shintaro Tajima2, Shinji Takenaka1,2 and Ken-ichi Yoshida1,2*Abstract
Background: Bacillus subtilis 168 possesses an efficient pathway to metabolize some of the stereoisomers of
inositol, including myo-inositol (MI) and scyllo-inositol (SI). Previously we reported a prototype of a B. subtilis cell
factory with modified inositol metabolism that converts MI into SI in the culture medium. However, it wasted half
of initial 1.0% (w/v) MI, and the conversion was limited to produce only 0.4% (w/v) SI. To achieve a more efficient SI
production, we attempted additional modifications.
Results: All “useless” genes involved in MI and SI metabolism were deleted. Although no elevation in SI production
was observed in the deletion strain, it did result in no wastage of MI anymore. Thus additionally, overexpression of
the key enzymes, IolG and IolW, was appended to demonstrate that simultaneous overexpression of them enabled
complete conversion of all MI into SI.
Conclusions: The B. subtilis cell factory was improved to yield an SI production rate of 10 g/L/48 h at least. The
improved conversion was achieved only in the presence of enriched nutrition in the form of 2% (w/v) Bacto
soytone in the medium, which may be due to the increasing demand for regeneration of cofactors.
Keywords: Bacillus subtilis, scyllo-inositol, myo-inositol, Bioconversion, Alzheimer’s diseaseBackground
Among the 9 inositol (1,2,3,4,5,6-cyclohexanehexol) ste-
reoisomers, myo-inositol (MI) is the most abundant in na-
ture (Figure 1). It serves as an indispensable structural
basis for a number of secondary messengers in eukaryotic
cells [1]. In contrast, the other inositol stereoisomers are
relatively rare, but some are known to exert specific
health-promoting effects. In particular, scyllo-inositol (SI)
has been regarded as a promising therapeutic agent for
Alzheimer’s disease [2], one of the most common and
problematic forms of dementia. Amyloid-beta (Aβ) aggre-
gation and amyloid formation in the brain are key patho-
logical features of Alzheimer’s disease [3]. SI directly
interacts with the Aβ peptide and blocks the development
of its fibrous aggregation [4]. In fact, oral administration
of SI to a mouse model of Alzheimer’s disease inhibited* Correspondence: kenyoshi@kobe-u.ac.jp
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stated.Aβ aggregation, attenuated Aβ-induced impairments of
spatial memory, reduced cerebral Aβ pathology, and
decreased the rate of mortality [2]. Therefore, SI has re-
ceived a fast-track designation from the US Food and
Drug Administration for treatment of mild to moderate
Alzheimer’s disease.
Bacillus subtilis is one of the best-studied Gram-positive
bacteria and has the ability to metabolize at least three in-
ositol stereoisomers including MI, SI, and D-chiro-inositol
(Figure 1) [5]. The B. subtilis iolABCDEFGHIJ operon en-
codes enzymes involved in multiple steps of inositol me-
tabolism, and transcription of the operon is regulated by
the IolR transcriptional repressor, whose gene is located
immediately upstream of the operon with divergent
orientation [6]. In the first step, MI is converted to
scyllo-inosose by the MI dehydrogenase IolG, with
NAD+ reduction. IolG also dehydrogenates D-chiro-
inositol to 1-keto-D-chiro-inositol, which is subsequently
isomerized by IolI to scyllo-inosose [7]. In the second
step, scyllo-inosose is dehydrated by IolE to 3D-(3,5/4)-
trihydroxycyclohexane-1,2-dione [8]. This intermediateLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Inositol metabolism in B. subtilis. B. subtilis iol genes encoding enzymes for reactions in the inositol catabolic pathway and the
respective intermediate compounds are shown. The symbols ↑ and Δ indicate over-expressed and deleted genes in KU106, respectively.
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IolA, resulting in intermediates that enter glycolysis
and the TCA cycle as dihydroxyacetone phosphate and
acetyl-CoA, respectively [9].
B. subtilis possesses two additional and distinct inosi-
tol dehydrogenases, IolX and IolW, which act specifically
on SI with NAD+ and NADP+ reduction, respectively
[10]. Each of these enzymes can convert SI to scyllo-ino-
sose, and scyllo-inosose is readily degraded further via
the metabolic pathway described above [10]. Inactivation
of iolX severely impairs cell growth depending on SI as
the carbon source, whereas inactivation of iolW does not
alter cell growth at all [10]. These results suggest thatIolX can play the major physiological role in SI catabol-
ism, whereas IolW may function through other mecha-
nisms, such as reduction of scyllo-inosose into SI with
oxidization of NADPH, as demonstrated in vitro [10].
In a previous study, we modified the metabolism of in-
ositol to construct strains that could convert MI into SI.
Strain TM039, a prototype of a cell factory, achieved the
maximum rate to convert nearly half of initial MI into SI
after 72 h of cultivation [5]. In this strain, three genes,
including iolR, iolX, and iolI, were disrupted and a mis-
sense mutation iolE41 was introduced. Those modifica-
tions were designed to enable constitutive expression of
the iolABCDEFGHIJ operon, including iolG, and to
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and dehydration of scyllo-inosose. Thus, MI was readily
dehydrogenated to scyllo-inosose, which was accumu-
lated and converted into SI by IolW, with the resulting
SI appearing in the medium. However, this strain was
found to consume and waste almost half of the MI ini-
tially contained in the medium [5].
In this study, we eliminated not only iolE but also all
the other iol genes required for the latter steps in the
metabolic pathway. We then overexpressed the two key
enzymes for the conversion, IolG and IolW, to increase
the conversion efficiency.Results and discussion
Deletion of iol genes irrelevant to the conversion of MI
into SI
Strain TM039, the prototype B. subtilis cell factory for
producing SI, is able to convert MI into SI [5]. However,
it appeared to waste half of the MI in the medium, given
that only 0.4% (w/v) SI remained after the conversion
from the initial 1.0% (w/v) MI (Table 1). We speculated
that this loss was due to the residual activity of scyllo-
inosose dehydratase encoded by iolE41 [8]. Because the
iolE41 allele could not support growth on MI as a sole
carbon source, we supposed that the IolE41 enzyme was
severely impaired. However, it was still possible that the
remaining limited activity of the mutated enzyme was
involved in the wastage of MI. With the aim of eliminat-
ing the possibility, not only iolE but also iolABCDFHIJ,
iolX, and iolR were deleted from the chromosome using
a marker-free deletion technique [11] to yield strain
MYI04. As expected, MYI04 did not waste MI after 48 h
of cultivation (Table 1), although the deletion did not
elevate the concentration of SI. We then speculated that
the limited conversion of MI into SI resulted not from
MI wastage but from the limited conversion capacity.Table 1 MI and SI contained in the culture media after
bioconversion









aThe medium initially contained 1.0% (w/v) MI. After 48 h of bioconversion,
concentrations of MI and SI were determined as described in the text. Values are
representative data from 3 independent measurements with similar results.
bND, not detected (<0.001%).
cConcentrations of MI and SI at 24 h of bioconversion.Overexpression of iolG and iolW
In addition to the above-mentioned deletion, we next
attempted to overexpress the two genes for the key en-
zymes IolG and IolW with the aim of enhancing the two
reactions involved in the conversion (Figure 1).
Global transcriptome analysis of B. subtilis grown
under 104 different growth conditions allowed us to
evaluate the strength and functional conditions of 2935
transcriptional promoters identified or predicted to date
[12]. Among this large number of promoters, we chose
two promoters of rpsO and rpoB, referred to as PrpsO
and PrpoB, respectively, for overexpression of iolG, judg-
ing them to be the strongest and constitutively active even
during stationary growth (Figure 2B). Strains KU101 and
KU102 were thus constructed, in which iolG was inte-
grated into the amyE locus and expressed under the con-
trol of PrpsO and PrpoB (PrpsO-iolG and PrpoB-iolG,
respectively). Both strains exhibited conversion rates al-
most equal to that of MYI04 (Table 1), indicating that in-
creasing expression of iolG alone was not sufficient to
improve the conversion.
Next, overexpression of iolW was tested similarly.
Overexpression of iolW markedly elevated the conver-
sion of MI into SI; concentrations of SI reached up to
0.85% (w/v) at 24 h in strain KU104 (PrpsO-iolW) and
0.80% (w/v) at 48 h in KU105 (PrpoB-iolW) cultures
(Table 1 and Figure 3A). These results suggested that
intracellular levels of the IolW enzyme could be one of
the important determinants in the conversion of MI into
SI and also that PrpsO performed slightly better than
PrpoB in overexpressing iolW. However, even the in-
creased supply of IolW enzyme did not result in the
conversion of all MI into SI. Accordingly, the additional
strain KU106, which simultaneously overexpressed iolG
and iolW under the control of PrpsO, was constructed.
KU106 achieved the ultimate conversion to yield 1.0% (w/v)
SI, equal to the initial concentration of MI (Figure 3B),
representing the best SI production rate of 10 g/L/48 h
at least. These results indicate that the synchronized ac-
celeration of the two reactions enabled by excess IolG
and IolW was required for the ultimate conversion.
Culture conditions enabling efficient conversion
In a previous study, when the major nutrient, 2% (w/v)
Bacto soytone, contained in the conversion medium was
reduced by half, no severe effect on cell growth was ob-
served, whereas SI production was impaired significantly
[5]. We conducted a similar test on the conversion per-
formed by KU106. As shown in Figure 3B, when the
amount of Bacto soytone in the medium was reduced by
one half and one quarter, SI production was reduced to
0.72% (w/v) and 0.52% (w/v), respectively. Given that the
two reactions in the conversion catalyzed by IolG and
IolW require reduction and oxidation of the cofactors
Figure 2 Construction of marker-free deletion mutants and overexpression strains of iolG and iolW. (A) Outline of the method for
construction of marker-free deletion mutants. (A-I) Positional relationship between target deletion and regions A, B, and C contained in the PCR
fragments used for construction of a marker-free deletion. A: upstream sequence; B: downstream sequence; C: sequence for integration of the
mazF cassette. (A-II) Recombinant PCR product using fragments A, B, C, and the mazF cassette. (A-III) Integrant of the mazF cassette at the target
region via a double crossover at regions A and C. An intrachromosomal single crossover event between the 2 directly repeated regions B results
in elimination of the mazF cassette as well as the target region. (A-IV) Final structure of marker-free deletion. (B) Organization of the iolG and iolW
overexpression cassettes. (B-I) For iolG overexpression, PCR fragments covering regions A + B (containing PrpsO or PrpoB) + C + D were ligated by
recombinant PCR and integrated into the amyE locus by a double crossover event. (B-II) For iolW overexpression, PCR fragments covering regions
E + F + G (PrpsO or PrpoB) + H + I were ligated and integrated into the aprE locus for construction of an iolW-overexpressing strain. (B-III) For
simultaneous overexpression of iolG and iolW, a PCR fragment covering regions A + B + C + H + D was ligated and integrated into the amyE locus.
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Figure 3 Time course of SI production and MI consumption along with cell growth. (A) Bioconversion from MI into SI was performed by
strains KU104 (PrpsO-iolW; squares), KU105 (PrpoB-iolW; diamonds), and KU106 (PrpsO-iolG iolW; triangles). Cell growth (optical density of cells:
closed symbols) and concentrations of MI (open symbols with dotted lines) and SI (open symbols with continuous lines) in the medium are
shown. (B) Bioconversion of MI into SI was performed by strain KU106 (PrpsO-iolG iolW) in the presence of various concentrations of Bacto
soytone; 2% (w/v) (triangles), 1% (circles), and 0.5% (squares). Cell growth (optical density of cells: closed symbols) and concentrations of MI
(open symbols with dotted lines) and SI (open symbols with continuous lines) in the medium are shown. A representative set of data from
three independent experiments with similar results is shown.
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suggest that higher concentrations of Bacto soytone
might be involved in the regeneration of NAD+ and
NADPH. Assuming there could be some mechanism for
cofactor regeneration, we are currently conducting an
intensive investigation.B. subtilis possesses two distinct inositol transporters,
IolT and IolF, which differ in substrate specificity to MI
and D-chiro-inositol [13,14]. In this study, we deleted
iolF to construct MYI04, and the results indicated that
iolF does not influence SI production and that iolT alone
was enough for the ultimate conversion. However, we
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growth medium and thus, plan to identify the as-yet un-
known efflux pump.
Conclusions
We have described the second generation of a B. subtilis
cell factory that permits SI production at a rate of
10 g/L/48 h at least. The cell factory contains multiple
deletions of many iol genes and simultaneous overex-
pression of iolG and iolW for the key reactions, enabling
efficient conversion of MI to SI. The highest conversion
efficiency was achieved only in the presence of enriched
nutrition in the form of 2% (w/v) Bacto soytone in the
medium.
Methods
Bacterial strains, culture conditions, and primers
Bacterial strains and oligonucleotide primers used in this
study are listed in Tables 2 and 3, respectively. Bacterial
strains were maintained in Luria–Bertani (LB) medium
[15]. Antibiotics, including 0.5 μg/mL erythromycin,
100 μg/mL spectinomycin, and 5 μg/mL chlorampheni-
col, were added as required, and 1 mM IPTG was also
added to the selection medium when needed. To per-
form the inositol bioconversion, 100 mL of bioconver-
sion medium, consisting of 2% (w/v) Bacto soytone
(Becton, Dickinson and Co., Sparks, MD), 0.5% (w/v)
Bacto yeast extract (Becton, Dickinson and Co.), 0.2%
(w/v) glucose, and 1% (w/v) MI, was added to a 500-mL
flask with baffles, inoculated with strains of B. subtilis at
an optical density of 0.05 at 600 nm, and incubated at
37°C with shaking at 200 rpm.
Mutant construction
MYI04 (ΔiolR, ΔiolABCDEF, ΔiolHIJ, ΔiolX) was con-
structed by employing the marker-free deletion tech-
nique [11]. First, approximately 500-bp fragments
located upstream (region A as indicated in Figure 2A-I)
and downstream (region B) of the target deletion were
amplified by PCR. Next, an additional fragment (region C)Table 2 Bacterial strains used in this study




TM039 iolE41 metC7 iolR::cat iolI::spc iolX::pMutin4(erm) [5]
MYI04 ΔiolABCDEF ΔiolHIJ ΔiolX ΔiolR This study
KU101 amyE:: PrpsO-iolG (cat) (MYI04 background) This study
KU102 amyE:: PrpoB-iolG (cat) (MYI04 background) This study
KU104 aprE:: PrpsO-iolW (erm) (MYI04 background) This study
KU105 aprE:: PrpoB-iolW (erm) (MYI04 background) This study
KU106 amyE:: PrpsO-iolG-iolW (cat) (MYI04 background) This studylocated immediately downstream of fragment A was amp-
lified. These three fragments and the mazF cassette, con-
sisting of mazF for suicidal toxin under the control of
IPTG-inducible promoter (Pspac), lacI for Lac repressor
controlling Pspac, and the spectinomycin resistance gene,
were ligated by recombinant PCR to generate a long frag-
ment containing the stretches corresponding to the regions
A, B, the mazF cassette, and C in that order, as shown in
Figure 2A-II. The recombinant PCR long fragments were
used to transform the parental B. subtilis strain to be spec-
tinomycin resistant via a double crossover in the homolo-
gous regions A and C, and thus the mazF cassette was
introduced into the targeted region (Figure 2A-III). The
spectinomycin-resistant transformants were then screened
on IPTG-containing plates for detection of spectinomycin-
sensitive mutants. In such mutants, an intrachromosomal
single crossover event between the two direct repeat
stretches corresponding to region B occurred to eliminate
the mazF cassette and resulted in marker-free deletion be-
tween regions A and B (Figure 2A-IV). To construct iolR
deletion, fragments of regions A, B, and C were amplified
using iolR-A-F/iolR-A-R, iolR-B-F/iolR-B-R, and iolR-C-F/
iolR-C-R primer pairs (Table 3), respectively. For iolABC-
DEF deletion, the primer pairs iolAF-A-F/iolAF-A-R,
iolAF-B-F/iolAF-B-R, and iolAF-C-F/iolAF-C-R, respect-
ively, were used. Similarly, for iolHIJ deletion, iolHIJ-A-F/
iolHIJ-A-R, iolHIJ-B-F/iolHIJ-B-R, and iolHIJ-C-F/iolHIJ-
C-R, respectively, were used, whereas for iolX deletion,
iolX-A-F/iolX-A-R, iolX-B-F/iolX-B-R, and iolX-C-F/iolX-
C-R, respectively, were used.
Strains KU104 and KU105 overexpressing iolG were
constructed as follows. Figure 2B-I shows the schematic
organization of the gene cassettes for overexpressing
iolG. DNA fragments corresponding to regions A, B, C,
and D were the elements of the cassette prepared by
PCR. The DNA fragment for region A was amplified
from the pCRE-test plasmid [16] by PCR using the pri-
mer pair amyE-1-F/amyE-1-R, and those for regions C
and D were amplified from the chromosomal DNA of
strain 168 using the pairs iolG-F/iolG-R2 and amyE-2-F/
amyE-2-R, respectively. For region B, two distinct frag-
ments containing PrpsO and PrpoB (referred to as B1 and
B2, respectively) were amplified from 168 DNA by PCR
using PrpsO-iolG-F/PrpsO-iolG-R and PrpoB-iolG-F/
PrpoB-iolG-R, respectively. Two sets of the four frag-
ments, covering the regions A + B1 + C +D and A + B2 +
C +D, were ligated by recombinant PCR using the outside
primers amyE-1-F and amyE-2-R. Each of the resulting
two recombinant PCR products possessed iolG under the
control of PrpsO or PrpoB flanked by N-terminal and C-
terminal regions of amyE gene at either end (Figure 2B-I).
Strain MYI04 was transformed to be chloramphenicol re-
sistant by a double crossover recombination at the amyE
locus to yield KU101 and KU102 as described [16].
Table 3 Oligonucleotide primers used in this study
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iolW were constructed as follows. Figure 2B-II shows
the gene cassette for iolW overexpression. DNA frag-
ments for the regions E, F, H, and I were amplified by
PCR using the primer pairs aprE-1-F/aprE-1-R, Em-F/
Em-R, iolW-F/iolW-R, and aprE-2-F/aprE-2-R, respect-
ively. Two fragments for regions G containing PrpsO and
PrpoB (referred to as G1 and G2, respectively) were ampli-
fied using PrpsO-iolW-F/PrpsO-iolW-R and PrpoB-iolW-
F/PrpoB-iolW-R, respectively. Two sets of the five frag-
ments, covering the regions E + F +G1 +H + I and E + F +
G2 +H + I, were ligated by recombinant PCR with the
outside primers of aprE-1-F and aprE-2-R and used to
transform MYI04 by a double crossover recombination at
the aprE locus to obtain KU104 and KU105, respectively.
Strain KU106, simultaneously overexpressing iolG and
iolW, was constructed as follows. DNA fragments for re-
gions A, B, and D were amplified by PCR as described
above (Figure 2B-I). Fragments for regions C and H were
amplified using the primer pairs iolG-F/iolG-R and
iolW-F-tail/iolW-R-tail, respectively (Figure 2B-I and II).
These five fragments, covering regions A + B + C +H+D,
were ligated by recombinant PCR with outside primers
of amyE-1-F and amyE-2-R. The resulting PCR product,
containing iolG and iolW genes under the control of
PrpsO flanked by the N-terminal and C-terminal re-
gions of amyE, was used to transform MYI04 by a
double crossover recombination at the amyE locus to
obtain KU106.
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Bacterial culture was diluted appropriately with pure
water when required, and cells were removed from the
culture medium by centrifugation. The supernatant was
mixed with AG 50 W-X8 resin (Bio-Rad, Hercules, CA)
for 1 h at 4°C, and then passed through an Amicon
Ultra-0.5 ml 3 K Centrifugal Filter (Millipore, Billerica,
MA). The eluent was subjected to high-performance li-
quid chromatography (LaChrom Elite: HITACHI High
Technologies, Tokyo, Japan) with refractive index detec-
tion using a Wakosil5NH2 column (4.6 × 250 mm)
(Wako Pure Chemical Industries, Osaka, Japan) main-
tained at 25°C with a flow of acetonitrile/water (80/20)
at 2 mL/min. The retention time was used to identify
the stereoisomers, and refractive index units were used
to calculate their concentrations.
Abbreviations
MI: myo-inositol; SI: scyllo-inositol; Aβ: Amyloid-beta.
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